STATE OF CONNECTICUT DEPARTMENT OF SOCIAL SERVICES

Notice of Proposed Medicaid State Plan Amendment (SPA)

SPA 25-D Pharmacy Value Based Purchasing (VBP) Supplemental Rebate Agreement

The State of Connecticut Department of Social Services (DSS) proposes to submit the following Medicaid State Plan Amendment (SPA) to the Centers for Medicare & Medicaid Services (CMS) within the U.S. Department of Health and Human Services (HHS). Public comment information is at the bottom of this document.

Changes to Medicaid State Plan

Effective on or after January 1, 2025, SPA 25-D will amend Attachment 3.1-A and 3.1-B in order to enter into a pharmacy value-based purchasing supplemental rebate agreement with manufacturers on a voluntary basis. The conditions of the value/outcomes-based contract shall be agreed upon by both the state and manufacturer.

The purpose of this SPA is to participate with CMS on this negotiated agreement with manufacturers in an attempt to get the most advantageous pricing on pharmaceuticals.

Fiscal Impact

Overall, DSS anticipates that this SPA will increase annual aggregate expenditures by approximately \$0 in State Fiscal Year (SFY) 2025 and \$0 in SFY 2026.

Obtaining SPA Language and Submitting Comments

The proposed SPA is posted on the DSS website at this link: <u>https://portal.ct.gov/DSS/Health-And-Home-Care/Medicaid-State-Plan-Amendments</u>. The proposed SPA may also be obtained at any DSS resource center, at the Town of Vernon Social Services Department, or upon request from DSS (see below).

To request a copy of the SPA from DSS or to send comments about the SPA, please email: <u>Public.Comment.DSS@ct.gov</u> or write to: Department of Social Services, Medical Policy Unit, 55 Farmington Avenue, 9th Floor, Hartford, CT 06105. Please reference "SPA 25-D Pharmacy Value Based Purchasing (VBP) Supplemental Rebate Agreement".

Anyone may send DSS written comments about this SPA. Written comments must be received by DSS at the above contact information no later than **January 29, 2025**.

Addendum Page 11c To Attachment 3.1 – A

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT State <u>CONNECTICUT</u>

AMOUNT, DURATION AND SCOPE OF SERVICES PROVIDED TO THE CATEGORICALLY NEEDY GROUP (S): <u>ALL</u>

- (8) Preferred Drug List with Prior Authorization
 - (a) Pursuant to 42 U.S.C. §1396r-8 and Section 17b-274d of the Connecticut General Statutes, as amended by Section 83 of Public Act 03-3 (June Special Session) and, effective August 1, 2004, as amended by Section 8 of Public Act 04-258, the State is establishing a preferred drug list with prior authorization for drugs not included on the preferred drug list as set forth in paragraph 12.a(6) above.
 - (b) Prior authorization may be established for certain drug classes, particular drugs or medically accepted indication for uses and doses.
 - (c) The State will appoint a Pharmaceutical and Therapeutics Committee in accordance with federal and state law.
- (9) Effective January 1, 2025, CMS has authorized the state of Connecticut to enter into value outcomes-based contracts with manufacturers on a voluntary basis. The conditions of the value/outcomes-based contract shall be agreed upon by both the state and manufacturer.

TN # <u>25-D</u> Supersedes TN # <u>11-020</u> Approval Date _____

Effective Date 01/01/2025

Addendum Page 11c To Attachment 3.1 – B

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT State <u>CONNECTICUT</u>

AMOUNT, DURATION AND SCOPE OF SERVICES PROVIDED TO THE MEDICALLY NEEDY GROUP (S): <u>ALL</u>

(8) Preferred Drug List with Prior Authorization

- (a) Pursuant to 42 U.S.C. §1396r-8 and Section 17b-274d of the Connecticut General Statutes, as amended by Section 83 of Public Act 03-3 (June Special Session) and, effective August 1, 2004, as amended by Section 8 of Public Act 04-258, the State is establishing a preferred drug list with prior authorization for drugs not included on the preferred drug list as set forth in paragraph 12.a(6) above.
- (b) Prior authorization may be established for certain drug classes, particular drugs or medically accepted indication for uses and doses.
- (c) The State will appoint a Pharmaceutical and Therapeutics Committee in accordance with federal and state law.
- (9) Effective January 1, 2025, CMS has authorized the state of Connecticut to enter into value outcomes-based contracts with manufacturers on a voluntary basis. The conditions of the value/outcomes-based contract shall be agreed upon by both the state and manufacturer.

TN # <u>25-D</u> Supersedes TN # <u>11-020</u> Approval Date _____

Effective Date 01/01/2025